Search clinical trials for: JNJ-69095897

Total 1098 results

Janssen Research & Development, LLC

Recruiting

A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) (FREESIA-1)

Thrombocytopenia, Neonatal Alloimmune

Spain, Belgium, Norway, Slovakia, Italy, Sweden
Janssen Research & Development, LLC

Recruiting

A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

Myasthenia Gravis

United States, Japan, Netherlands, Poland
Janssen Research & Development, LLC

Completed

A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Janssen Research & Development, LLC

Completed

A Study of JNJ-77474462 (Bermekimab) in Healthy Participants of Japanese Descent Following Administration of Single Ascending Subcutaneous Doses

Healthy

Australia
Janssen Research & Development, LLC
Bristol-Myers Squibb

Completed

A Study of JNJ-70033093 in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Active, not recruiting

A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

Urothelial Carcinoma

France, United States, Korea, Republic of, Belgium, Taiwan, Turkey, Russian Federation, Spain, Italy, United Kingdom, Brazil, Belarus, Poland
Crucell Holland BV

Completed

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers

Respiratory Tract Infections | Respiratory Syncytial Viruses

United States
Janssen Research & Development, LLC

Completed

A Study to Investigate the Whole Body Distribution and Radiation Dosimetry of the Positron Emission Tomography Ligand Fluoride-18 (18F)-JNJ-64326067 in Healthy Participants

Healthy

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer

Prostate Adenocarcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Testosterone Greater Than 150 ng/dL

United States
Janssen Research & Development, LLC

Completed

A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease

Respiratory Syncytial Viruses

Taiwan, Belgium, United Kingdom, Argentina, Panama
Janssen Research & Development, LLC
Bristol-Myers Squibb

Completed

A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery (AXIOMATIC-TKR)

Arthroplasty, Replacement, Knee

Israel, Belgium, Italy, United States, Spain, Hungary, Portugal, Russian Federation, Japan, Turkey, Ukraine, Greece, Poland, Argentina, Brazil, Bulgaria, Canada, South Africa
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection (OSPREY)

Hepatitis B, Chronic

France, Belgium, Italy, United Kingdom, Poland, Spain, New Zealand, Taiwan
Johnson & Johnson Enterprise Innovation Inc.

Recruiting

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

Carcinoma, Non-small-Cell Lung

Korea, Republic of, United States, Spain, Germany
Janssen Research & Development, LLC

Completed

A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis

Arthritis, Rheumatoid

United Kingdom, United States, Spain, Germany, Poland
Janssen Research & Development, LLC
Bristol-Myers Squibb

Recruiting

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)

Acute Coronary Syndrome

United States, Taiwan, Korea, Republic of, Italy, South Africa, Israel, Belgium, Argentina, Malaysia, Romania, Serbia, China, Australia, Netherlands, United Kingdom, Denmark, Czechia, Hungary, Japan, France, Canada, Bulgaria, Spain, T... and more
Janssen Research & Development, LLC
Bristol Myers Squibb Company (BMS)

Recruiting

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK)

Ischemic Stroke; Ischemic Attack, Transient

Italy, United States, Hong Kong, Canada, Japan, China, Taiwan, South Africa, Korea, Republic of, Israel, United Kingdom, Argentina, Belgium, New Zealand, Australia, Germany, Czechia, Denmark, Mexico, Croatia, France, Brazil, Hungary, ... and more
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Relapsed or Refractory Multiple Myeloma | Previously Treated Amyloid Light-chain (AL) Amyloidosis

Belgium, United States, United Kingdom, Spain, France, Netherlands
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Lymphoma, Non-Hodgkin | Leukemia, Lymphocytic, Chronic, B-Cell

United States, China, France, Denmark, Israel, Poland, Australia
Janssen Research & Development, LLC

Completed

A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, Spain, Germany
Janssen Research & Development, LLC

Completed

A Study of JNJ-77242113 Following Oral Administration in Healthy Chinese Adult Participants

Healthy

China
Janssen Research & Development, LLC

Completed

A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors

Neoplasms

Spain, Israel
Janssen Research & Development, LLC

Completed

A Study to Assess the Effect of Seltorexant Compared to Placebo on Respiration During Sleep in Adult Participants With Obstructive Sleep Apnea

Sleep Apnea, Obstructive

United States
Janssen Research & Development, LLC

Completed

A Study of Apalutamide Administered Orally as Whole Tablets and as a Mixture in Applesauce in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Safety, Tolerability and Pharmacokinetics Study of a Single Intravenous Dose of JNJ-49122944 in Healthy Male Participants

Healthy

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Dose-Ranging Study of JNJ-40411813 in Healthy Male Volunteers

Healthy

Netherlands
Janssen Sciences Ireland UC

Completed

An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection

Hepatitis B

United States, Korea, Republic of, France, Belgium, Italy, Taiwan, United Kingdom, Thailand, Malaysia, China, Spain, Canada, Germany, Japan, Russian Federation, Turkey, Ukraine, Poland, Hong Kong
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate Skin Irritation and Photo Irritation of JNJ 10229570-AAA on Intact Skin of Japanese Healthy Male Participants

Healthy Volunteers

Japan
Janssen Research & Development, LLC

Recruiting

A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) (AZALEA)

Hemolytic Disease of the Fetus and Newborn

Israel, Netherlands, Japan, United States, Australia, Belgium, United Kingdom, Brazil, Germany
Janssen Research & Development, LLC

Recruiting

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

United States, China, Taiwan, Korea, Republic of, Japan, France, Portugal, Spain, Czechia, Greece, Poland, United Kingdom
Janssen Research & Development, LLC

Recruiting

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

Myasthenia Gravis

United States, Korea, Republic of, Japan, Taiwan, Denmark, Germany, Czechia, China, Spain, Belgium, Canada, Mexico, Poland, Italy, France, Australia, Sweden
Janssen Research & Development, LLC

Completed

A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants

Healthy

United States
Janssen Vaccines & Prevention B.V.

Completed

An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults

Healthy

United Kingdom
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-61393215 in Healthy Japanese Male Participants

Healthy

Japan
Janssen Pharmaceutica N.V., Belgium

Completed

A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-64041575 in Adult Participants With Various Degrees of Renal Function

Renal Insufficiency

Germany
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-87890387 for Advanced Solid Tumors

Advanced Solid Tumors

United States, France, Spain
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

Neoplasms | Myeloproliferative Disorders | Essential Thrombocythemia | Myelofibrosis

United States, Spain, United Kingdom, France, Canada
Merck Sharp & Dohme LLC

Recruiting

A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)

Hepatic Impairment | Non-alcoholic Steatohepatitis

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Lymphoma, Non-Hodgkin | Leukemia, Lymphocytic, Chronic, B-Cell

United States, Korea, Republic of, United Kingdom, Taiwan, Israel, Spain, Australia, France
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2 (Amplify)

Coronavirus Disease

United States
Janssen Scientific Affairs, LLC

Available

Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

Multiple Myeloma
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S in Healthy Adults (COVID-19)

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study of JNJ-64300535 in Healthy Participants

Healthy

Belgium
Janssen Pharmaceutical K.K.

Completed

A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant

Japan
Janssen Research & Development, LLC

Terminated

A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer

Advanced Cancer

United States
Janssen Research & Development, LLC

Terminated

Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma

Healthy | Asthma

United States
Janssen Research & Development, LLC

Recruiting

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (MonumenTAL-1)

Hematological Malignancies

United States, Belgium, Korea, Republic of, China, Germany, Israel, Netherlands, Japan, Spain, France, Poland
Janssen Pharmaceutical K.K.

Active, not recruiting

A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Janssen Research & Development, LLC

Active, not recruiting

A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (RAGNAR)

Advanced Solid Tumor

France, United States, Japan, Belgium, United Kingdom, Germany, Taiwan, China, Korea, Republic of, Poland, Italy, Spain, Australia, Brazil, Argentina
Janssen Research & Development, LLC

Active, not recruiting

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

Neoplasms

United Kingdom, Spain, United States, Russian Federation, Poland, Sweden, Moldova, Republic of
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis (ICONIC-LEAD)

Plaque Psoriasis

Germany, United States, Hungary, Italy, Turkey, Korea, Republic of, United Kingdom, China, Taiwan, Poland, Canada, France, Australia, Spain, Argentina, Japan

Search clinical trials for: JNJ-69095897

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations